Skip to content

Exact Sciences Corp. of Marlborough said it has achieved the $15 million milestone associated with the national commercial availability of PreGen-Plus, which is intended for early detection of colorectal cancer.

This is the second $15 million milestone achieved in connection with the licensing agreement Exact Sciences and Laboratory Corp. of America Holdings entered into in June 2002. PreGen-Plus is Exact Sciences' proprietary DNA-based stool assay for the early detection of colorectal cancer.

Exact Sciences is a biotech company that applies genomics to solve large clinical needs. Its DNA-based assay, PreGen-Plus, is intended for the early detection of colorectal cancer in the average-risk population. The company also has developed PreGen-26, intended to detect colorectal cancer in a high-risk group of patients.